LBI-HTA - Publications - Search - Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)

Rothschedl, E. (2018): Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 84.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
749Kb
Abstract

Castration-resistant prostate cancer (CRPC) is a prostate cancer that keeps growing even when the testosterone level is reduced to very low levels. Enzalutamide (Xtandi®) is an orally bioavailable, organic, non-steroidal small-molecule androgen receptor (AR) signalling inhibitor. The US Food and Drug Administration (FDA) approved enzalutamide for nonmetastatic and metastatic CRPC in July 2018. To date, enzalutamide is not yet approved by the European Medicines Agency (EMA) for the assessed indication.

The PROSPER trial assessed the efficacy and safety of enzalutamide versus placebo in patients with nonmetastatic CRPC and a rapidly rising prostate-specific antigen (PSA) level. Analyses showed that patients of the enzalutamide group had a statistically significant benefit in median metastasis-free survival (MFS) (HR 0.29, 95% CI, 0.24–0.35, p < 0.001); hence, patients who received enzalutamide had a 71% lower risk of metastasis or death than patients who received the placebo. Patients of the enzalutamide group also had a statistically significant delay regarding the median time to PSA progression (HR 0.07, 95% CI, 0.05–0.08, p < 0.001) and the median time to first use of subsequent antineoplastic therapy (HR 0.21, 95% CI, 0.17–0.26, p < 0.001). For overall survival (OS), only data from the first interim analysis is available; at that point of time, 11% of the patients of the enzalutamide group and 13% of placebo-group patients had died. The median OS was not reached in either treatment group. One third of enzalutamide-group patients had an adverse event (AE) of grade 3 or higher. Serious AEs were more frequent among patients of the enzalutamide group than in placebo-group patients (24% vs. 18%); 3% of enzalutamide patients had an AE that led to death, compared to 1% in the placebo group.

The administration of enzalutamide in patients with nonmetastatic CRPC and a rapidly rising PSA prolonged MFS and delayed PSA progression and the use of subsequent antineoplastic therapy. However, the clinical benefit of enzalutamide reflected in OS prolongation and an improvement of the patients’ quality of life (QoL) has not been established yet. Final analyses of the PROSPER trial and further ongoing studies may provide information about whether prolonged MFS also implies prolongation of OS. At any rate, the benefits of enzalutamide treatment need to be weighed against the risks, always considering the patients’ QoL. Additionally, a direct comparison of enzalutamide and apalutamide is needed to verify the optimal treatment for this patient population.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:Enzalutamide, Xtandi®, prostate cancer, castration-resistant, nonmetastatic
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
WJ Urogenital system > WJ 700-875 Male genitalia
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:DSD: Horizon Scanning in Oncology 84
Deposited on:20 Dec 2018 13:01
Last Modified:20 Dec 2018 13:01

Repository Staff Only: item control page